MedPath

Vancomycin

Generic Name
Vancomycin
Brand Names
Firvanq, Vancocin
Drug Type
Small Molecule
Chemical Formula
C66H75Cl2N9O24
CAS Number
1404-90-6
Unique Ingredient Identifier
6Q205EH1VU
Background

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].

Indication

Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).

Associated Conditions
Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
Clinical Trials
Related News

Fecal Microbiota Transplantation Shows Promise in Preventing Graft-versus-Host Disease After Stem Cell Transplants

• A phase 2 clinical trial demonstrates that oral fecal microbiota transplantation (FMT) is a safe and feasible approach to prevent graft-versus-host disease (GVHD) in stem cell transplant recipients. • The study identifies donor-specific effects, with FMT from Donor 3 showing the highest microbiota engraftment rate and a favorable safety profile. • Lower pre-FMT microbiota diversity in patients was associated with better donor microbiota engraftment, suggesting a more receptive gut environment for transplanted microbes. • The ongoing randomized phase of the trial will further investigate FMT's impact on reducing severe GVHD, improving quality of life, and increasing survival rates.

MaaT013 Shows Promise in Phase 3 Trial for GI-aGvHD

• MaaT Pharma's MaaT013 met its primary endpoint in the Phase 3 ARES trial, demonstrating a 62% gastrointestinal overall response rate (GI-ORR) in patients with GI-aGvHD. • The study showed a 54% estimated 12-month overall survival rate, with responders at day 28 exhibiting a significantly higher survival rate of 67% compared to non-responders. • MaaT Pharma plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in mid-2025 for MaaT013 as a third-line treatment. • The ARES trial represents the first positive pivotal clinical study for a microbiome-based approach in GI-aGvHD, potentially offering a new treatment option for patients.

Recursion's AI-Driven C. diff Candidate REC-3964 Enters Phase II Trials

• Recursion's REC-3964, an AI-developed, non-antibiotic small molecule, has entered Phase II clinical trials for recurrent Clostridioides difficile (C. diff) infection. • REC-3964 selectively inhibits the glucosyltransferase activity of toxin B produced by C. diff, offering a novel mechanism of action compared to traditional antibiotics. • The Phase II ALDER trial will assess the safety, tolerability, pharmacokinetics, and efficacy of REC-3964 in reducing C. diff recurrence, with results expected in Q4 2025. • Unlike antibiotics, REC-3964 targets the bacterial toxin while sparing the gut microbiome, potentially minimizing adverse events and reducing the risk of recurrent infections.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy